Overview of a 5-year clinical experience with a yeast-derived hepatitis B vaccine
- 1 March 1990
- Vol. 8, S74-S78
- https://doi.org/10.1016/0264-410x(90)90222-8
Abstract
No abstract availableKeywords
This publication has 18 references indexed in Scilit:
- Persistence of antibodies after immunization with a recombinant yeast-derived hepatitis B vaccine following two different schedulesVaccine, 1990
- Protective efficacy of a recombinant DNA hepatitis B vaccine in neonates of HBe antigen-positive mothersJAMA, 1989
- Persistence of antibodies following vaccination with a yeast-derived recombinant hepatitis B vaccineVaccine, 1988
- Lack of Induction of IgE and IgG Antibodies to Yeast in Humans Immunized with Recombinant Hepatitis B VaccinesInternational Archives of Allergy and Immunology, 1988
- BOOSTING PROPERTIES OF RECOMBINANT DNA HEPATITIS B VACCINEThe Lancet, 1986
- PREVENTION OF PERINATALLY TRANSMITTED HEPATITIS B VIRUS INFECTIONS WITH HEPATITIS B IMMUNE GLOBULIN AND HEPATITIS B VACCINEThe Lancet, 1983
- Summary of worldwide clinical experience with H-B-Vax® (B, MSD)Journal of Infection, 1983
- Synthesis and assembly of hepatitis B virus surface antigen particles in yeastNature, 1982
- RANDOMISED PLACEBO-CONTROLLED TRIAL OF HEPATITIS B SURFACE ANTIGEN VACCINE IN FRENCH HAEMODIALYSIS UNITS: I, MEDICAL STAFFThe Lancet, 1981
- Hepatitis B VaccineNew England Journal of Medicine, 1980